Latest News

CMS: Receipt of Eligibility-To-List Letter from the SGX-ST
2025-06-27

CMS: Receipt of Eligibility-To-List Letter from the SGX-ST

On 25 June 2025, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) received an eligibility-to-list letter (“ETL”) from the Singapore Exchange Securities Trading Limited (the “SGX-ST”) in respect of the Proposed Secondary Listing and, subject to fulfilment of the conditions set out therein, the Shares are expected to be listed and to commence trading on the SGX-ST on around 15 July 2025. The ETL is not an indication of the merits of the Proposed Secondary Listing, the Group and/or the Shares.   The Proposed Secondary Listing will not involve issuance of new Shares, and the Shares will continue to be listed and traded on the Hong Kong Stock Exchange thereafter.   The Directors believe that upon completion of the Proposed Secondary Listing on the SGX-ST, the Group will be able to attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia, thereby optimizing the shareholder structure. At the same time, it will also have a more […]

Learn More
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange
2025-06-24

China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange

The board of directors of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) announces the proposed secondary listing of the Company’s ordinary shares (“Shares”) on the Singapore Exchange Securities Trading Limited (the “SGX-ST”) by way of introduction (the “Proposed Secondary Listing”). The Proposed Secondary Listing, if proceeded, will not involve issuance of new shares, and the Shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter. The Company has submitted, on a confidential basis, an application to the SGX-ST in relation to the Proposed Secondary Listing. As of the date of this announcement, the Company has not received the eligibility-to-list letter (“ETL”) from the SGX-ST in respect of the Proposed Secondary Listing. On June 24, 2025, the Company received the Notice of Overseas Issuance and Listing Filing (境外發行上市備案通知書) from the China Securities Regulatory Commission (the “CSRC”) in respect of […]

Learn More
CMS Charity | Lighting Up the Stars for Exceptional Children and Rural Education with Love
2025-06-02

CMS Charity | Lighting Up the Stars for Exceptional Children and Rural Education with Love

As the International Children’s Day approaches, China Medical System Holdings Limited (“CMS”)  has once again partnered with the Charity Association of Shenzhen Nanshan to visit Shenzhen Nanshan Star Exceptional Children Rehabilitation Center and Shenzhen Nanshan Exceptional Children Care Center, donating dedicated funds to both institutions. The donation will be used to purchase toys and teaching aids, upgrade office facilities, and sponsor advanced training for outstanding teachers to enhance the professionalism of special education staff. CMS has continuously supported the growth and development of exceptional children, and is wholeheartedly committed to playing a role in fostering a learning environment brimming with love and warmth for the children. Simultaneously, CMS is actively responding to China’s “Hundreds, Thousands, Tens of Thousands Project,” which aims to promote rural revitalization. Through the Guangdong Education Foundation, CMS has donated a total of 18 sets of laptops and desktop computers to Caojiang No. 2 Middle School in Gaozhou for the construction of a Loving Language Laboratory, enabling students to better […]

Learn More

The news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.

All News